ResMed announces PAP therapy reduces hospitalizations by 31%, ER visits by 23%

In collaboration with leading medical researchers from around the world, ResMed presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health. “The real-world evidence used in our clinical research continues to demonstrate the effectiveness of PAP therapy for treating OSA,” said Carlos Nunez, MD, ResMed’s Chief Medical Officer. “The studies presented at SLEEP 2024 expand our understanding of patients with sleep disorders by examining critical areas such as the effect of demographic factors like gender on sleep health. The body of knowledge we have created and are continually expanding with research partners who are highly respected in their fields helps ResMed and the medical community achieve the goal of helping people live their healthiest lives.”